Support Us — Your donation helps us keep running

Goal: 1000 CNY,Raised: 1000 CNY

100.0%
Get alerts for future matching vulnerabilitiesLog in to subscribe
I. Basic Information for CVE-2017-1371
Vulnerability Information

Have questions about the vulnerability? See if Shenlong's analysis helps!
View Shenlong Deep Dive ↗

Although we use advanced large model technology, its output may still contain inaccurate or outdated information.Shenlong tries to ensure data accuracy, but please verify and judge based on the actual situation.

Vulnerability Title
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Description
Builder tools running in the IBM TRIRIGA Application Platform 3.3, 3.4, and 3.5 contains a vulnerability that could allow an authenticated user to execute Builder tool actions they do not have access to. IBM X-Force ID: 126864.
Source: NVD (National Vulnerability Database)
CVSS Information
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Type
N/A
Source: NVD (National Vulnerability Database)
Vulnerability Title
IBM TRIRIGA Application Platform Builder工具安全漏洞
Source: CNNVD (China National Vulnerability Database)
Vulnerability Description
IBM TRIRIGA Application Platform是美国IBM公司的一套用于部署TRIRIGA应用的技术平台。该平台提供了一组设计时和运行时组件,分别用于构建和运行其企业级应用,并支持客户特定的配置,而无需更改源代码。Builder tools是其中的一个开发工具。 IBM TRIRIGA Application Platform中的Builder工具存在安全漏洞。远程攻击者可利用该漏洞操作Builder工具。以下版本受到影响:IBM TRIRIGA Application platform
Source: CNNVD (China National Vulnerability Database)
CVSS Information
N/A
Source: CNNVD (China National Vulnerability Database)
Vulnerability Type
N/A
Source: CNNVD (China National Vulnerability Database)
Affected Products
VendorProductAffected VersionsCPESubscribe
IBMTRIRIGA Application Platform 3.3.2 -
II. Public POCs for CVE-2017-1371
#POC DescriptionSource LinkShenlong Link
AI-Generated POCPremium

No public POC found.

Login to generate AI POC
III. Intelligence Information for CVE-2017-1371
Please Login to view more intelligence information
New Vulnerabilities
V. Comments for CVE-2017-1371

No comments yet


Leave a comment